Long-term results in children with AML: NOPHO-AML Study Group - Report of three consecutive trials

Leukemia

Volumn 19, Issue 12, 2005, Pages 2090-2100

  Lie, S O ^a   Abrahamsson, J ^b   Clausen, N ^c   Forestier, E ^d   Hasle, H ^c   Hovi, L ^e   Jonmundsson, G ^f   Mellander, L ^b   Siimes, M A ^e   Yssing, M ^g   Zeller, B ^a   Gustafsson, Goran ^h  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^c AARHUS UNIVERSITY   (Denmark)

^d UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF HELSINKI   (Finland)

^f Department of Pediatrics ^*  (Iceland)

^g Rigshospitalet   (Denmark)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acute myeloid leukaemia; Children; Cytogenetic; Dose intensity; Stem cell transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; MITOXANTRONE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE ASSOCIATION; DOWN SYNDROME; DRUG EFFICACY; DRUG RESPONSE; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

EID: 28544443076     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2403962     Document Type: Article

References (29)

1. Lie SO. Treatment of acute myeloid leukaemia in children. Baillière's Clin Paediatr 1996; 3: 757-778.
2. Lie SO, Berglund G, Gustafsson G, Jonmundsson G, Siimes M, Yssing M. High-dose Ara-C as a single-agent consolidation therapy in childhood acute myelogenous leukemia. Hemat Bluttransf 1990; 33: 215-221.
3. Lie SO, Jonmundsson G, Mellander L, Siimes MA, Yssing M, Gustafsson G. A population-based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: Best outcome in girls, infants, and children with Down's syndrome. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Br J Haematol 1996; 94: 82-88.
4. Lie SO, Abrahamsson J, Clausen N, Forestier E, Hasle H, Hovi L et al. Treatment stratification based on initial in vivo response in acute myeloid leukemia in children without Down's syndrome: Results of NOPHO-AML trials. Br J Haematol 2003; 122: 217-225.
5. Creutzig U, Ritter J, Zimmermann M, Reinhardt D, Hermann J, Berthold F et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: Results of Study Acute Myeloid Leukemia - Berlin-Frankfurt-Munster 93. J Clin Oncol 2001; 19: 2705-2713.
6. Stevens RF, Hann IM, Wheatley K, Gray RG. Marked improvements in outcome with chemotherapy alone in Pediatric acute myeloid leukemia: Results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol 1998; 101: 130-140.
7. Webb DK, Harrison G, Stevens RF, Gibson BG, Hann IM, Wheatley K. Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood 2001; 98: 1714-1720.
8. Woods WG, Kobrinsky N, Buckley JD, Lee JW, Sanders J, Neudorf S et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: A report from the Children's Cancer Group. Blood 1996; 87: 4979-4989.
9. Lie SO, Slördahl SH. Vitamin A and/or high-dose Ara-C in the maintenance of remission in acute myelogenous leukemia in children. Scand J Haematol 1984; 33: 256-259.
10. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR et al. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 1985; 103: 626-629.
11. Hasle H, Niemeyer CM, Chessells JM, Baumann I, Bennett JM, Kerndrup G et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003; 17: 277-282.
12. Hasle H, Baumann I, Bergstrasser E, Fenu S, Fischer A, Kardos G, et al, European Working Group on childhood MDS. The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). Leukemia 2004; 18: 2008-2014.
13. Abbott BL, Rubnitz JE, Tong X, Srivastava DK, Pui CH, Ribeiro RC et al. Clinical significance of central nervous system involvement at diagnosis of pediatric acute myeloid leukemia: A single institution's experience. Leukemia 2003; 17: 2090-2096.
14. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD et al. Report of the National Cancer Institute-sponsored workshop on definitions and response in acute myeloid leukemia. J Clin Oncol 1990; 8: 813-819.
15. Nourusis MJ. SPSS Statistical Software. SPSS: Base and Advanced Statistics 11.5. Chicago: SPSS Inc., 2002.
16. Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001; 97: 56-62.
17. Lehrnbecher T, Varwig D, Kaiser J, Reinhardt D, Klingebiel T, Creutzig U. Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia 2004; 18: 72-77.
18. Creutzig U, Zimmermann M, Ritter J, Henze G, Graf N, Loffler H et al. Definition of a standard-risk group in children with AML. Br J Haematol 1999; 104: 630-639.
19. Wells RJ, Arthur DC, Srivastava A, Heerema NA, Le Beau M, Alonzo TA et al. Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children's Cancer Group Study 213. Leukemia 2002; 16: 601-607.
20. Drobyski WR. The role of allogeneic transplantation in high-risk acute myelogenous leukemia. Leukemia 2004; 18: 1565-1568.
21. Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JH et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: Results of the UK MRC AML 10 trial. Br J Haematol 2002; 118: 385-400.
22. Raimondi SC, Chang MN, Ravindranath Y, Behm FG, Gresik MV, Steuber CP et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: Clinical characteristics and treatment outcome in a cooperative Pediatric Oncology Group Study-POG 8821. Blood 1999; 94: 3707-3716.
23. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood 1998; 92: 2322-2333.
24. Pui CH, Raimondi SC, Srivastava DK, Tong X, Behm FG, Razzouk B et al. Prognostic factors in infants with acute myeloid leukemia. Leukemia 2000; 14: 684-687.
25. Rubnitz JE, Raimondi SC, Tong X, Srivastava DK, Razzouk BI, Shurtleff SA et al. Favorable impact of the t(9;11) in childhood acute myeloid leukemia. J Clin Oncol 2002; 20: 2302-2309.
26. Palle J, Frost BM, Forestier E, Gustafsson G, Nygren P, Hellebostad M et al. Nordic Society for Paediatric Haematology and Oncology. Cellular drug sensitivity in MLL-rearranged childhood acute leukaemia is correlated to partner genes and cell lineage. Br J Haematol 2005; 129: 189-198.
27. Feller N, van der Pol MA, van Stijn A, Weijers GW, Westra AH, Evertse BW et al. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 2004; 18: 1380-1390.
28. van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: Principles, approaches, and laboratory aspects. Leukemia 2003; 17: 1013-1034.
29. Viehmann S, Teigler-Schlegel A, Bruch J, Langebrake C, Reinhardt D, Harbott J. Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement. Leukemia 2003; 17: 1130-1136.